Comparison of 48 ‐week efficacies of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and nucleoside/nucleotide reverse transcriptase inhibitor‐sparing regimens: a systematic review and network meta‐analysis

HIV Medicine, EarlyView.

Source: HIV Medicine - July 13, 2018 Category: Infectious Diseases Authors: S Gallien , M Massetti , P Flandre , H Leleu , D Descamps , E Lazaro Source Type: research